Back to top

Image: Bigstock

Can HubSpot (HUBS) Run Higher on Strong Earnings Estimate Revisions?

Read MoreHide Full Article

HubSpot, Inc. (HUBS - Free Report) is cloud-based marketing and sales software platform that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on HUBS’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that HUBS International could be a solid choice for investors.

Current Quarter Estimates for HUBS

In the past 30 days, four estimates have gone higher for HubSpot compared to two lower in the same time period. The trend has been pretty favorable too, with estimates increasing from 6 cents a share 30 days ago, to 7 cents a share today, a move of 16.7%.

Current Year Estimates for HUBS

Meanwhile, HubSpot’s current year figures are also looking quite promising, with seven estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, increasing from 17 cents per share 30 days ago to 19 cents per share today, an increase of 11.8%.

HubSpot, Inc. Price and Consensus

Bottom Line

The stock has also started to move higher lately, adding 10.13% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Investor Alert: Breakthroughs Pending

A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.

Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.

Click here to see them >>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


HubSpot, Inc. (HUBS) - free report >>

Published in